| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adb0e564374fedf34b36103d36e6455a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02E50-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02E50-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02E50-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P2201-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-242
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P7-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P7-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P7-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P7-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-30 |
| filingDate |
2019-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_386d3c5367e987284d981b7d6aa1ed01 |
| publicationDate |
2020-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020048671-A1 |
| titleOfInvention |
Process for enzymatic hydrolysis of lignocellulosic material and fermentation of sugars |
| abstract |
A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma. |
| priorityDate |
2014-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |